Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
Source: Cofisem - Last Update: 2023-05-05
Key Executives
| Chairman and Chief Executive Officer | |
| Chief Financial Officer | |
| Human Resources Director | |
| Company Secretary |
Source: Cofisem - Last Update: 2022-10-11
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net sales | 25,556,211 | 24,112,504 | 20,105,049 | 20,046,256 | 19,345,334 |
| Cost of sales | 5,299,347 | 5,829,212 | 3,723,127 | 4,174,629 | 4,242,912 |
| Personnal costs | 0 | ||||
| Operating income | 6,866,575 | 8,758,389 | 3,315,147 | 3,828,157 | 7,169,148 |
| Income tax | 1,169,098 | 1,834,158 | 1,286,645 | -182,166 | 2,044,956 |
| Net income | 4,277,323 | 5,475,980 | 72,476 | 4,789,884 | 4,773,604 |
| Net consolidated income (Group share) | 4,301,680 | 5,497,174 | 100,163 | 4,809,530 | 4,769,232 |
| Fiscal year end | 12.22 | 12.21 | 12.2 | 12.19 | 12.18 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards |
Source: Cofisem - Last Update: 2023-05-05
Shareholder information
| BlackRock, Inc. | |
| Capital Research Global Investors | |
| The Vanguard Group, Inc. |
Source: Cofisem - Last Update: 2023-05-05
Address
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California
United States
Phone number: +1 650 574 3000
Fax: +1 650 578 9264
http://www.gilead.com
Source: Cofisem - Last Update: 2023-05-05
Please contact MyQuestion.Italy@euronext.com for Company Profile support.